Radiotherapy Expertise in Pharmatest
Having successfully worked with radioactive compounds for almost a decade, Pharmatest has strong expertise in testing efficacy of radiotherapies in preclinical oncology models, which was demonstrated in a recent scientific publication in collaboration with Bayer.
Pharmatest is a contract research organisation that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. In oncology, Pharmatest has strong expertise in bone metastasis models.
Pharmatest has almost a decade of experience in testing efficacy of radioactive compounds in preclinical efficacy models. The studies have provided a large amount of scientific publications, including published papers in scientific journals, oral presentations, and posters in leading scientific events.
The latest scientific paper was published in collaboration with Bayer in August 2017 in Clinical Cancer Research, demonstrating efficacy of radium-223 dichloride (Xofigo) to inhibit prostate cancer growth in bone microenvironment. The study continues the long collaboration between Pharmatest and Bayer in radiotherapy field. The efficacy of Xofigo has been confirmed in clinical studies and Xofigo is currently in use in castration-resistant prostate cancer patients with advanced bone metastatic disease.
CEO of Pharmatest Jussi Halleen says: “I am proud of the strong expertise of Pharmatest for testing efficacy of radiotherapies in preclinical studies.
“Setting up the capacity, training the personnel, and obtaining the required licenses in compliance with relevant legislation has required lots of efforts over the years, and we can firmly state to be among the global leaders in the field.”